{"id":"W2133117185","doi":"10.1093/infdis/jiu051","title":"Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study","year":2014,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":329,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; Gilead Sciences; ViiV Healthcare; GlaxoSmithKline; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Elvitegravir; Dolutegravir; Raltegravir; Medicine; Discontinuation; Regimen; Tolerability; Integrase inhibitor; Adverse effect; Viral load; Internal medicine; Population; Phases of clinical research; Pharmacology; Clinical trial; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002716881,0.0006355991,0.001200625,0.0001516822,0.0002413681,0.0009595718,0.0003576308,0.0007998176,0.0009682601],"category_scores_gemma":[0.001968984,0.0002398762,0.001162949,0.0002440687,0.0003141311,0.000428433,0.0002192961,0.001390056,0.0002927514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005219165,"about_ca_system_score_gemma":0.0006612555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008268401,"about_ca_topic_score_gemma":0.001457695,"domain_scores_codex":[0.9994522,0.0002721369,0.00004185886,0.00006974957,0.00008671101,0.00007741949],"domain_scores_gemma":[0.9987084,0.0003027176,0.0003129238,0.000106805,0.0001316039,0.0004377088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6086246,0.02454543,0.1287211,0.001169324,0.004189043,0.0003891129,0.0007428493,0.003568289,0.04565663,0.0002412626,0.005691173,0.1764613],"study_design_scores_gemma":[0.3051788,0.2904577,0.3834071,0.0001962401,0.002200502,0.0008978997,0.0002046292,0.004126358,0.006289971,0.0002546872,0.006674829,0.0001113047],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945951,0.003139118,0.0002293594,0.000162206,0.00003506593,0.0003216242,0.0007395669,0.00002810016,0.0007497898],"genre_scores_gemma":[0.9961659,0.0007823291,0.000511136,0.0003690296,0.00004673126,0.00020544,0.001397432,0.00001369943,0.0005082047],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002716881,"threshold_uncertainty_score":0.01436841,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008909296242199214,"score_gpt":0.2590626394812267,"score_spread":0.2501533432390275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}